

Quality Measures 2023

Provider Reference Guide for Healthcare Effectiveness Data & Information Set (HEDIS) related quality measures

Information below provides guidance to evidence-based services and related coding to support quality

Children and Adolescents		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
	Percentage of children two years of age with appropriate childhood immunizations on or before their second birthday:	DTaP Vaccine CPT: 90697, 90698,90700, 90723 IPV Vaccine CPT: 90697, 90698,90713, 90723 MMR Vaccine CPT: 90707, 90710; HIB Vaccine CPT: 90644, 90647, 90648, 90697, 90698, 90748 Hepatitis B Vaccine CPT: 90633, 90697, 90723, 90740, 90744, 90747, 90748; HCPCS: G0010 VZV Vaccine CPT: 90710, 90716 Pneumococcal Conjugate Vaccine CPT: 90670, 90671; HCPCS:G0009 Hepatitis A Vaccine CPT: 90633 Rotavirus 2 Dose Schedule Vaccine CPT: 90681; Rotavirus 3 Dose Schedule Vaccine CPT: 90680 Influenza Vaccine CPT: 90655, 90657, 90661, 90673, 90674, 90685-90689, 90756; HCPCS: G0008

Children and Adolescents		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) Commercial & Medicaid Members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year: 	 There must be documentation at least once during the measurement year of the following: 1. Height and weight in the measurement year and BMI percentile 2. Counseling for nutrition 3. Counseling for physical activity 	BMI Percentile ICD-10 Codes: Z68.51 – Z68.54 Nutrition Counseling CPT: 97802-97804 ICD-10 Code: Z71.3 HCPCS Codes: S9470, S9452, S9449, G0270, G0271,G0447 Physical Activity Counseling ICD-10 Code: Z02.5, Z71.82 HCPCS Codes: G0447, S9451
 BMI percentile documentation Counseling for nutrition Counseling for physical activity 	Exclusion: Pregnancy	



Children and Adolescents		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Immunizations for Adolescents (IMA) • Commercial & Medicaid Adolescents who received recommended vaccinations on or before their 13th birthday.	 The percentage of adolescents 13 years of age with appropriate immunizations on or by their 13th birthday: 1 - meningococcal vaccine between 11th and 13th birthdays 1 - Tdap vaccine between 10th and13th birthdays 2 - HPV vaccines at least 146 days apart between 9th and 13th birthdays, <u>or</u> 3 HPV vaccines on different dates of service between 9th and 13th birthdays Exclusions: Anaphylactic reaction: ICD-10: T80.52XA, T80.52XD, and T80.52XS 	Meningococcal CPT:90619, 90733, 90734 Tdap CPT: 90715 HPV CPT: 90649, 90650, 90651
Lead Screening in Children (LSC) • Medicaid Children 2 years of age who had one or more lead screening by their second birthday.	At least one lead capillary or venous blood test on or before the child's second birthday. Documentation in the medical record must include the following: Note indicating the date the test was performed Result or finding Exclusions: N/A	Lead Screening Test CPT: 83655



Children and Adolescents		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Child and Adolescent Well- Care Visits (WCV) • Commercial & Medicaid The percentage of members 3-21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.	At least one well-care visit during the year. Exclusions: N/A	Well-Care CPT: 99381-99385, 99391-99395, 99461; HCPCS: G0438, G0439, S0302, S0610, S0612, S0613; ICD-10: Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z01.1411, Z01.419, Z02.5, Z76.1, Z76.2
 Well-Child Visits in the First 30 Months of Life (W30) Commercial & Medicaid The percentage of members who had the following number of well-child visits with a PCP during the last 15 months: six or more well-child visits for members who turned 15 months old during the measurement year and two or more well-child visits for members who turned 30 months during the measurement year. 	 First 15 Months: At least six well-care visits before the 15-month birthday. Months 15-30: At least two well care visits. Exclusions: N/A 	Well-Care CPT: 99381-99385, 99391-99395, 99461; HCPCS: G0438, G0439, S0302; ICD-10: Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z02.5, Z76.1, Z76.2



Women's Health and Maternity		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
	 Required Service/Documentation Prenatal Care A diagnosis of pregnancy must be present. Documentation in the medical record must include evidence of ONE of the following: A basic physical obstetrical exam that includes auscultation of fetal heart tone, measurement of fundus height, or a pelvic exam with obstetric observations Evidence that a prenatal care procedure was performed such as an obstetric panel, or TORCH antibody panel alone, or a rubella antibody test/titler with a Rh incompatibility (ABO/Rh) blood typing, or ultrasound of a pregnant uterus Documentation indicating pregnancy such as: prenatal flow sheet, LMP, EDD, gestational age, gravidity and parity, complete obstetrical history, prenatal risk assessment and counseling/education, or a positive pregnancy test result. Postpartum Visit Must occur on or between 7 and 84 days after delivery. Documentation in the medical record must have ONE of the following: Pelvic exam Evaluation of weight, BP, breasts and abdomen Notation of PPC, including, but not limited to: "postpartum care", "6-week check", or a preprinted PP form Perineal or cesarean incision check Screening for depression, anxiety, substance use disorder, tobacco use, or preexisting mental health disorders Glucose screening for women with gestational diabetes. Documentation of family planning or intercourse resumption, infant care or breastfeeding, sleep/fatigue, healthy weight attainment, physical activity resumption 	Prenatal Prenatal Bundled Services* CPT: 59400, 59425, 59426, 59510, 59610, 59618; HCPCS: H1005 Stand Alone Prenatal Visits CPT: 99500; CPT-CAT-II: 0500F, 0501F, 0502F; HCPCS: H1000- H1004 Prenatal Visits CPT: 99201-99205, 99211-99215, 99241-99245, 99483; HCPCS: G0463, T1015 Telephone Visit CPT (with a pregnancy-related diagnosis code): 98966, 98967, 98968, 99441, 99442, 99443 Online Assessment CPT (with a pregnancy-related diagnosis code): 98969-98972, 98980, 98981, 99421-99423, 99444, 99457, 99458; HCPCS: G0071,G2010, G2012, G2061, G2062, G2063, G2250, G2251, G2252 Postpartum Postpartum Visits CPT: 57170, 58300, 59430, 99501; CPT-CAT-II: 0503F; HCPCS: G0101; ICD-10: Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2 Cervical Cytology Lab Test CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175; HCPCS: G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091; Postpartum Bundled Services* CPT: 59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622 (Exclusions: services provided in an
		acute inpatient setting) *WV Medicaid requires pre and post visits be billed separately.



Women's Health and Maternity		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Cervical Cancer Screening (CCS) Commercial & Medicaid Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following: Women 21-64 years of age who had cervical cytology performed within the last three years Women 30-64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last five years Women age 30-64 who had cervical cytology/ high-risk human papillomavirus (hrHPV) co-testing performed within the last five years 	Cervical cytology/HPV co- testing must occur on the same claim and date of service (DOS). Exclusions: <u>Hysterectomy</u> CPT: 57530, 57531,57540, 57545,57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240,58260, 58262, 58263, 58290-58294, 58548, 58550,58552- 58554, 58570-58575, 58951,58953, 58954,58956, 59135 ICD-10: Q51.5, Z90.710, Z90.712	Cervical Cytology CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 <u>HPV Test</u> CPT: 87624, 87625 HCPCS: G0476



Women's Health and Maternity		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Chlamydia Screening in Women (CHL) • Commercial & Medicaid Percentage of sexually active women 16-24 with annual chlamydia screening during measurement year.	Sexually active women ages 16- 24 should have at least one chlamydia test a year. The CHL measure is driven by administrative capture and not medical record review. Exclusions: Pregnancy test and a prescription for isotretinoin on the date of the pregnancy test or the six days after the test; pregnancy test and diagnostic radiology	<u>Chlamydia Tests</u> CPT: 87110, 87270, 87320, 87490-87492, 87810, 0353U
Adults		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Colorectal Cancer Screening (COL) • Commercial, Medicaid & Medicare Percentage of members 45-75 years of age who had appropriate screening for colorectal cancer.	 At least one of the following screenings in the appropriate time frame: FOBT during the measurement year Flexible sigmoidoscopy within the past five years Colonoscopy within the past 10 years Colonography within the past 10 years CT colonography within the past five years sDNA FIT Test within the past three years sDNA FIT Test within the past three years Exclusions: <u>History of Colorectal Cancer</u> ICD-10: C18.0-C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048 <u>Total Colectomy</u> CPT: 44150-44153, 44155-44158, 44210-44212 ICD-10: ODTEOZZ, ODTE4ZZ, ODTE7ZZ, ODTE8ZZ 	FOBT Lab Test CPT: 82270, 82274 HCPCS: G0328 sFIT DNA Lab Test CPT: 81528 CT Colonography CPT: 74261-74263 Flexible Sigmoidoscopy CPT: 45330-45335, 45337, 45338, 45340-45342, 45346, 45347, 45349, 5350 HCPCS: G0104 ICD9PCS: 45.24 Colonoscopy CPT: 44388-44394, 44397, 44401-44408, 45355, 45378-45393 45398 HCPCS: G0105, G0121 ICD9PCS: 45.22, 45.23, 45.25, 45.42, 45.43



Adults		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Care for Older Adults (COA) • Medicare DSNP Percentage of adults 66 years and older who had each of the following during the measurement year: • Medication review (includes a medication list and a review or transitional care management services) • Functional status assessment • Pain assessment	 There must be documentation of all of the following: Medication review (includes a medication list and a review or transitional care management services) Functional status assessment Pain assessment Exclusions: Medication review, functional status assessment, and pain assessment during acute inpatient stay 	Medication Review CPT: 90863, 99483, 99605, 99606 CPT-CAT-II: 1160F Medication List HCPCS: G8427 CPT-CAT-II: 1159F Transitional Care Management Services CPT: 99495, 99496 (exclude services provided in an acute inpatient setting) Functional Status Assessment CPT: 99483 HCPCS: G0438, G0439 CPT-CAT-II: 1170F (exclude services provided in an acute inpatient setting) Pain Assessment CPT-CAT-II: 1125F, 1126F (exclude services provided in an acute inpatient setting)



Adults		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Advance Care Planning (ACP) • Medicare The percentage of adults 66–80 years of age with advanced illness, an indication of frailty or who are receiving palliative care, and adults 81 years of age and older who had advance care planning during the measurement year.	Evidence of advance care planning during the measurement year	Advance Care Planning CPT: 99483, 99497 HCPCS: S0257 CPT-CAT-II: 1123F, 1124F, 1157F, 1158F ICD-10: Z66



Respiratory Conditions		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Appropriate Testing for Pharyngitis (CWP) Commercial, Medicaid & Medicare Percentage of members 3 years or older diagnosed with pharyngitis, 	Exclusions: N/A Pharyngitis DX: ICD-10: J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91	<u>Group A Strep Test</u> CPT: 87070, 87071, 87081, 87430, 87650-87652, 87880
prescribed an antibiotic, and tested for strep. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR) • Commercial, Medicaid & Medicare	Exclusions: N/A	<u>Spirometry</u> CPT: 94010, 94014-94016, 94060, 94070, 94375
Percentage of members 40 years or order with a new diagnosis of COPD or newly active COPD who received appropriate spirometry testing to confirm the diagnosis during the last two years.		



Respiratory Conditions		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Pharmacotherapy Management of COPD Exacerbation (PCE) • Commercial, Medicaid & Medicare Members dispensed systemic corticosteroid within 14 days or bronchodilator within 30 days of an acute inpatient discharge or ED encounter with a principal diagnosis of COPD.	Inpatient or ED visit with primary discharge of COPD. Exclusions: N/A	Systemic Corticosteroid Medications Glucocorticoids (cortisone- acetate, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisolone, prednisone) Bronchodilator Medications Anticholinergic agents (aclidinium bromide, ipratropium, tiotropium, umeclidinium) Beta 2-Agonists Albuterol, arformoterol, formoterol, indacaterol, levalbuterol, metaproterenol, salmeterol, olodaterol Bronchodilator Combinations Albuterol-ipratropium, budesonide-formoterol, fluticasone-vilanterol, fluticasone-vilanterol, fluticasone furoate- umeclidinium-vilanterol, formoterol-aclidinium, formoterol-glycopyrrolate, olodaterol hydrochloride, olodaterol-tiotropium, umeclidinium-vilanterol)



Respiratory Conditions		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Asthma Medication Ratio (AMR) • Commercial & Medicaid Percentage of members 5- 64 years of age with asthma who had a ratio of controller medications to total asthma medications of .5 or greater.	Service/Documentation	Asthma Controller <u>Medications</u> Anti-asthmatic combinations (Dyphylline-guaifenesin), antibody inhibitors (Omalizumab), anti- interleukin-4 (Dupilumab), anti-interleukin-5 (Benralizumab, Mepolizumab, Reslizumab), inhaled steroid combinations (Budesonide- formoterol, Fluticasone- salmeterol, Fluticasone- vilanterol, Formoterol- mometasone), inhaled corticosteroids (Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone, Mometasone), leukotriene modifiers (Montelukast, Zafirlukast, Zileuton), methylxanthines (Theophylline) <u>Asthma Reliever Medications</u> Short-acting, inhaled beta-2 agonists (Albuterol,



Cardiovascular		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Controlling High Blood Pressure (CBP) • All LOB Percentage of members age 18-85 with diagnosis of hypertension and whose most recent blood pressure during the measurement year was controlled (<140/90 mm Hg).	18–85 years of age whose last blood pressure in the measurement year was <140/90 mm Hg. Document blood pressure readings every visit for members 18–85 years of age with a diagnosis of hypertension. Repeat uncontrolled blood pressure readings.	Systolic Blood Pressure CPT-CAT-II: 3074F; 3075F, 3077F and Diastolic Blood Pressure CPT-CAT-II: 3078F, 3079F, 3080F During one of the following: Outpatient CPT: 99201-99205, 99211- 99215, 99241-99245, 99341- 99345, 99347-99350, 99381- 99387, 99391-99397, 99401- 99404, 99411, 99412, 99429, 99455, 99456, 99483; HCPCS: G0402, G0438, G0439, G0463, T1015 Telephone Visit CPT: 98966-98968, 99441- 99443 Online Assessment CPT: 98969-98972, 98980, 98981, 99421- 99423, 99444, 99457,99458; HCPCS: G0071, G2010, G2012, G2061, G2062, G2063, G2250- G2252



Cardiovascular		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Persistence of Beta-Blocker Treatment after a Heart Attack (PBH)• Commercial, Medicaid & MedicarePercentage of members 	Exclusions: Asthma; COPD; chronic respiratory conditions due to fumes or vapors; beta-blocker contraindications; asthma exclusions medications: bronchodilator combinations (Budesonide-formoterol, Fluticasone-vilanterol, Fluticasone-salmeterol, Formoterol-mometasone), inhaled corticosteroids (Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone, Mometasone); adverse effect of beta- adrenoreceptor antagonists	Beta Blocker Medications: Non-cardio-selective beta- blockers (Carvedilol, Labetalol, Nadolol, Pindolol, Propranolol, Timolol, Sotalol), cardio-selective beta blockers (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol), anti- hypertensive combinations (Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol- hydrochlorothiazide, Hydrochlorothiazide- metoprolol, Hydrochlorothiazide- propranolol)
Statin Therapy for Patients with Cardiovascular Disease (SPC)• Commercial, Medicaid & MedicareThe percentage of males 21-75 years of age and females 40-75 years of age with clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high or moderate intensity statin medication during the measurement year and remained on medication for at least 80% of the treatment period.	Exclusions: N/A	High-Intensity Statin Therapy Medications Atorvastatin 40-80 mg, Amlodipine-atorvastatin 40-80 mg, Rosuvastatin 20-40 mg, Simvastatin 80 mg, Ezetimibe-simvastatin 80 mg Moderate-Intensity Statin Therapy Medications Atorvastatin 10-20 mg, Amlodipine-atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Ezetimibe-simvastatin 20-40 mg, Pravastatin 40-80 mg, Lovastatin 40 mg, Fluvastatin 40-80 mg, Pitavastatin 2–4 mg



Cardiovascular		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Cardiac Rehabilitation (CRE) • Commercial, Medicaid & Medicare The percentage of members age 18 and older who attended cardiac rehabilitation following a qualifying cardiac event (including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement).	Initiation: At least 2 sessions from event date through 30 days. Engagement 1: At least 12 sessions from event date through 90 days. Engagement 2: At least 24 sessions from event date through 180 days. Achievement: At least 36 sessions from event date through 180 days. Exclusions: N/A	 Four rates reported: 1. Initiation (2 sessions) 2. Engagement 1 (12 sessions) 3. Engagement 2 (24 sessions) 4. Achievement of (36 sessions) Cardiac Rehabilitation CPT: 93797, 93798 HCPCS: G0422, G0423, S9472



Diabetes		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Hemoglobin A1c Control for Patients with Diabetes (HBD) Commercial, Medicaid & Medicare The percentage of members 18-75 years of age with diabetes whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year: HbA1c control (<8.0%) HbA1c poor control (>9.0%) 	year prior and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes.	HbA1c Test CPT: 83036, 83037 HbA1c Test Result CPT-CAT-II: 3044F, 3046F, 3051F, 3052F
Blood Pressure Control for Patients with Diabetes (BPD) • Commercial, Medicaid & Medicare The percentage of members 18-75 years of age with diabetes whose blood pressure was adequately controlled (140/90 mm Hg) during the measurement year.	The most recent blood pressure performed during the measurement year. Exclusions: No diagnosis of diabetes during the measurement year or the year prior and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes.	Systolic Blood Pressure CPT-CAT-II: 3074F, 3075F, 3077F Diastolic Blood Pressure CPT-CAT-II: 3078F, 3079F, 3080F
 Eye Exam for Patients with Diabetes (EED) Commercial, Medicaid & Medicare The percentage of members 18-75 years of age with diabetes who had a retinal eye exam. 	A screening for diabetic retinal disease in the measurement year or a screening in the prior year with a negative result. Or a bilateral eye enucleation any time. Retinal exams must be performed or interpreted by an eye care professional. Exclusions: No diagnosis of diabetes during	Eye Exams – Diabetic Retinal Screening CPT: 67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92201, 92202, 92227-92228, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242-99245; HCPCS: S0620, S0621, S3000 Eye Exam with Evidence of Retinopathy CPT-CAT-II: 2022F, 2024F, 2026F Eye Exam without Evidence of Retinopathy CPT-CAT-II: 2023F, 2025F, 2033F
	the measurement year or the year prior and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes.	Image: Market Streening Negative in the Prior Year CPT-CAT-II: 3072F Unilateral Eye Enucleation CPT: 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114



Diabetes		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Kidney Health Evaluation for Patients with Diabetes (KED) • Commercial, Medicaid & Medicare The percentage of diabetic members 18-85 years of age who received a kidney health evaluation including an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR) during the measurement year.	Exclusions: N/A	Estimated Glomerular Filtration Rate Lab Test CPT: 80047, 80048, 80050, 80053, 80069, 82565 Quantitative Urine Albumin Lab Test CPT: 82043 Urine Creatinine Lab Test CPT: 82570
Statin Therapy for Patients with Diabetes (SPD) • Commercial, Medicaid & Medicare The percentage of diabetic members 40-75 years of age who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one statin medication during the measurement year and remained on medication for at least 80% of the treatment period.	Exclusions: N/A	High Intensity Statin Therapy MedicationsAtorvastatin 40-80 mg, Amlodipine-atorvastatin 40- 80 mg, Rosuvastatin 20-40 mg, Simvastatin 80 mg, Ezetimibe-simvastatin 80 mgModerate Intensity Statin Therapy Medications Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Rosuvastatin 20-40 mg, Ezetimibe-simvastatin 20-40 mg, Pravastatin 40-80 mg, Lovastatin 40 mg, Fluvastatin 40-80 mg, Pitavastatin 2–4 mgLow-Intensity Statin Therapy Medications Ezetimibe-simvastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10 mg, Fluvastatin 20 mg, Pravastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10 mg, Fluvastatin 20 mg, Pravastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10-20 mg, Simvastatin 5-10 mg



Musculoskeletal		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Osteoporosis Management in Women Who Had a Fracture (OMW) Medicare Percentage of women 67- 85 years of age who suffered a fracture and received appropriate osteoporosis treatment as indicated by one of the following: Bone mineral density test within six months of the fracture or during the inpatient stay if fracture occurred during hospitalization Osteoporosis therapy within six months of the fracture Long-acting osteoporosis therapy during the inpatient stay if fracture occurred during hospitalization Adispensed prescription to treat osteoporosis within six months of the fracture	Exclusions: N/A	Bone Mineral Density Test CPT: 76977, 77078, 77080, 77081, 77085, 77086 Osteoporosis Medication Therapy HCPCS: J0897, J1740, J3110, J3489, J3111 Long-Acting Osteoporosis Medications HCPCS: J0897, J1740, J3489 Dispensed an Osteoporosis Medication Bisphosphonates (Alendronate, Alendronate- cholecalciferol, Ibandronate, Risedronate, Zoledronic acid), other agents (Abaloparatide, Denosumab, Raloxifene, Romosozumab, Teriparatide)
Osteoporosis Screening in Older Women (OSW) • Medicare Percentage of women 65- 75 years of age who received osteoporosis screening.	Exclusions: N/A	Osteoporosis Screening Test CPT: 76977, 77078, 77080, 77081, 77085



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Antidepressant Medication Management (AMM) • Commercial, Medicaid & Medicare Percentage of members 18 years or older diagnosed with depression who remained on antidepressant for at least six months. • Acute Phase Treatment • Continuation Phase Treatment *This measure is a 12- month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year.	Exclusions: N/A Acute Phase Treatment: Members who remained on an antidepressant medication for at least 84 days (12 weeks). Continuation Phase Treatment: Members who remained on an antidepressant medication for at least 180 days (6 months).	Antidepressant Medications Miscellaneous antidepressants (Bupropion, Vilazodone, Vortioxetine), monoamine oxidase inhibitors (Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine), phenylpiperazine antidepressants (Nefazodone, Trazodone), psychotherapeutic combinations (Amitriptyline- chlordiazepoxide, amitriptyline-perphenazine, Fluoxetine-olanzapine), SNRI antidepressants (Desvenlafaxine, Duloxetine, Levomilnacipran, Venlafaxine), SSRI antidepressants (Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline), tetracyclic antidepressants (Maprotiline, Mirtazapine), tricyclic antidepressants (Amitriptyline, Amoxapine, Clomipramine, Desipramine, Nortriptyline, Protriptyline, Trimipramine)



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Exclusions: Narcolepsy	Initiation Visit – Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72 BH Outpatient Visit CPT: 98960-98962, 99078, 99201-
Commercial & Medicaid		99205, 99211-99215, 99241- 99245, 99341-99345, 99347- 99350, 99381-99387, 99391-
Percentage of children 6-		99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510; HCPCS:
12 years of age with newly prescribed ADHD medication who received the appropriate follow-up visits to include an		G0155, G0176, G0177, G0409, G0463,G05812,H0002, H0004, H0031,H0034, H0036, H0037, H0039,H0040, H2000, H2010, H2011, H2013-H2020, T1015
initiation visit within 30 days of the prescription dispensing date and two visits within nine months of the initiation visit.		Observation CPT: 99217, 99218, 99219, 99220 Health and Behavior Assessment or Intervention CPT: 96150-96159, 96164, 96165,
*This measure is a 12- month window starting onMarch 1 of the year prior to the measurement yearand ending the last day of February of the measurement year.		Cri: 98130-98139, 98184, 98183, 96167, 96168, 96170, 96171 Partial Hospitalization POS: 52 Partial Hospitalization or Intensive Outpatient HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 <u>Community Mental Health</u> <u>Center</u> POS: 53 <u>Telehealth Visit</u> POS: 02 <u>Telephone Visit</u> CPT: 98966, 98967, 98968, 99441, 99442, 99443 <u>Maintenance Visit</u> Any of the above codes or <u>Online Assessment</u> CPT: 98969-98972, 99421-99423, 99444, 9945; HCPCS: G0071, G2010, G2012, G2061, G2062, G2063



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
		Any of the following with a mental health provider: Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72 BH Outpatient Visit CPT: 98960-98962, 99078, 99201- 99205, 99211-99215, 99241- 99245, 99341-99345, 99347- 99350, 99381-99387, 99391- 99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510; HCPCS:G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 Partial Hospitalization POS: 52 Partial Hospitalization or Intensive Outpatient HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 Community Mental Health Center POS: 53 Electroconvulsive Therapy CPT: 90870 Telehealth Visit POS: 02 Telephone Visit CPT: 98966, 98967, 98968, 99441,
		99442, 99443 Observation CPT: 99217, 99218, 99219, 99220 <u>Transitional Care Management</u> Services CPT: 99495, 99496 <u>Behavioral Healthcare Setting</u> UBREV: 0513, 0900, 0901, 0902, 0903, 0904, 0905, 0907, 0911, 0912, 0913, 0914, 0915, 0916, 0917, 0919



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Follow-Up After Emergency DepartmentVisit for Mental Illness (FUM) • Commercial, Medicaid & Medicare Percentage of ED visits for members 6 years of age and older with a principaldiagnosis of mental illnessor intentional self-harm who had a follow-up visit for mental illness within 7 and 30 days.		Any of the following with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentionalself-harm and any diagnosis of a mental health disorder: <u>Outpatient</u> POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72 <u>BH Outpatient Visit</u> CPT: 98960-98962, 99078, 99201- 99205, 99211-99215, 99241- 99245, 99341-99345, 99347- 99350, 99381-99387, 99391- 99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510; HCPCS:G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031,H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013- H2020, T1015 <u>Partial Hospitalization</u> POS: 52 <u>Partial Hospitalization or Intensive Outpatient</u> HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 <u>Community Mental Health</u> <u>Center</u> POS: 53 <u>Electroconvulsive Therapy</u> CPT: 90870 <u>Telehealth Visit</u> POS: 02 <u>Telephone Visit</u> CPT: 98966, 98967, 98968, 99441, 99442, 99443; <u>Observation</u> CPT: 99217, 99218, 99219, 99220 <u>Online Assessment</u> CPT: 98969-98972, 98980, 98981, 99421-99423, 99444, 99457, 99458; HCPCS: G0071, G2010, G2012, G2061, G2062, G2063, G2251, G2252



Behavioral Health

Follow-Up After HighIntensity Care for Substance UseDisorder (FUI)Exclusions: N/AAny of the following with a principal diagnosis of substance use disorder: Inpatient Stay UBREY: 0100, 0101, 0110-0114, 0116-0124, 0126-0134, 0136-0144, 0146-0154, 0156-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199- 0204, 0206-0214, 0219, 1000-1002• Commercial,Medicaid & MedicareExclusions: N/AAny of the following with a principal diagnosis of substance use disorder: Inpatient Stay UBREY: 0100, 0101, 0110-0114, 0116-0124, 0126-0134, 0136-0144, 0146-0154, 0136-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199- 0204, 0206-0214, 0219, 1000-1002Percentage of acuteinpatient hospitalizations, residential treatment, or detoxification visitsfor a diagnosis of substance use disorder among members 13 years of age and older that result in a follow-up visit within 7 and 30days.Figure 4000 Figure
IET Visits CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99239, 99251-99255Observation CPT: 99217, 99218, 99219, 99220Residential Behavioral Health Treatment HCPCS: H0017, H0018, H0019, T2048Telephone Visit CPT: 98966, 98967, 98968, 99441, 99442, 99443Online Assessment CPT: 98969-98972, 99421-99423, 99444, 99458; HCPCS: G2010, G2012, G2061, G2062, G2063 A pharmacotherapy dispensing event of medication treatment event [Medications: Naîtrexone (oral & injectable), Buprenorphine/naloxone (sublingual tablet, injection, implant), Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film), Buprenorphine/naloxone (sublingual tablet, Acamprosate (oral and injectable), Acamprosate (oral and delayed-release tablet)]



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Follow-Up After Emergency Department Visit for Substance Use (FUA) • Commercial, Medicaid & Medicare Percentage of emergency department visits for members 13 years of age or older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence who had a follow up visit for AOD within 7 and 30 days.	Exclusions: N/A	Any of the following with a principal diagnosis of AOD abuse or dependence: IET Stand Alone Visits CPT: 98960-98962, 99078, 99201- 99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384- 99387, 99394-99397, 99401-99404, 99408-99409, 99411, 99412, 99483, 99510; HCPCS: G0155, G0176, G0177, G0396, G0397, G0409, G0410, G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2010- H2020, H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012; UBREV: 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0907, 0911- 0917, 0919, 0944, 0945, 0982, 0983 OUD Weekly Non-Drug Service HCPCS: G2071, G2074-G2077, G2080 OUD Monthly Office Based Treatment HCPCS: G2067-G2070, G2072, G2073 IET Visits CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251- 99255 Observation CPT: 99217, 99218, 99219, 99220 Telephone Visit CPT: 98966, 98967, 98968, 99441, 99442, 99443 Online Assessment CPT: 98969-88972, 98980, 98981, 99421- 99423, 99444, 99457, 99458; HCPCS: G0071, G2010, G2012, G2061-G2063, G2010, G2012, G2250, G2250-G2252



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Pharmacotherapy for Opioid Use Disorder (POD)• Commercial, Medicaid & MedicarePercentage of new opioid use disorder pharmacotherapy events with OUD pharmacotherapy for 180 	Exclusions: N/A	Opioid Use Disorder Treatment Medications Naltrexone oral medications, naltrexone injection medications, buprenorphine oral medications, buprenorphine implant medications, buprenorphine naloxone medication, methadone.
Diabetes Screening for People with Schizophrenia or Bipolar Who Are Using Antipsychotic Meds (SSD) • Medicaid Percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed on antipsychotic medication and had a diabetes screening test during the measurement year.	Exclusions: N/A	<u>Glucose Lab Test</u> CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 <u>HbA1c Lab Test</u> CPT: 83036, 83037; CPT-CAT- II: 3044F, 3046F, 3051F, 3052F
Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) Medicaid Percentage of members 18-64 years of age with schizophrenia or schizoaffective disorder and diabetes who had an LDL-C test and an HbA1c test during the measurement year.	Exclusions: No diagnosis of diabetes during the measurement year or the year prior and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes	HbA1c Lab Test CPT: 83036, 83037; CPT-CAT- II: 3044F, 3046F, 3051F, 3052F <u>LDL-C Lab Test</u> CPT: 80061, 83700, 83701, 83704, 83721; CPT-CAT-II: 3048F, 3049F, 3050F



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)	Exclusions: N/A	LDL-C Lab Test CPT: 80061, 83700, 83701, 83704, 83721; CPT-CAT-II: 3048F, 3049F, 3050F
• Medicaid Percentage of members 18-64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease who had an LCL- C test during the during the measurement year.		
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA) • Commercial, Medicaid & Medicare Percentage of members 18 years and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.	Exclusions: Dementia Diagnosis	Dementia Medication Donepezil, Galantamine, Rivastigmine, Memantime, Donepezil-memantine Oral Antipsychotic Medications Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, lioperidone, Loxapine, Lurisadone, Molindone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Amitriptyline-perphenazine, Thiothixene
		Long-Acting Injections Risperidone, Aripiprazole, Fluphenazine decanoate, Haloperidol deconoate, Olanzapine, Paliperidone palmitate; HCPCS: J2794, J0401, J1631, J1943, J1944, J2358, J2426, J2680, J2798



Behavioral Health		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Commercial & Medicaid Percentage of children and adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing including at least one of the following during the measurement year: Blood glucose testing Cholesterol testing 	Exclusions: N/A	Glucose Lab Test CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c Lab Test CPT: 83036, 83037; CPT-CAT- II: 3044F, 3046F, 3051F, 3052F LDL-C Lab Test CPT: 80061, 83700, 83701, 83704, 83721; CPT-CAT-II: 3048F, 3049F, 3050F Cholesterol Lab Test CPT: 82465, 83718, 83722, 84478
 Diagnosed Mental Health Disorders (DMH) Commercial, Medicaid & Medicare The percentage of members 1 year of age and older who were diagnosed with a mental health disorder during the measurement year. 	Exclusions: N/A	N/A



Care Coordination		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
DefinitionTransitions of Care (TRC)• MedicarePercentage of discharges during the measurement year for members 18 years of age and older who had each of the following:• Notification of inpatient admission 	Service/Documentation Exclusions: N/A	Patient Engagement Outpatient CPT: 99201-99205, 99211- 99215, 99241-99245, 99341- 99345, 99347-99350, 99381- 99387, 99391-99397, 99401- 99404, 99411, 99412, 99429, 99455, 99456, 99483; HCPCS: G0402, G0438, G0439, G0463, 11015 Telephone Visit CPT: 98966-98968, 99441- 99443 Transitional Care Management Services CPT: 99495, 99496 Online Assessment CPT: 98969-98972, 98980, 98981, 99421-99423, 99444, 99457, 99458; HCPCS:G2010, G2012, G2061, G2062, G2063, G0071, G2251, G2252 Medication Reconciliation CPT: 99483, 99495, 99496; CPT: Q143, 99495, 99496;
discharge (within 30 days after discharge)		



Medication Management		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Follow up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC) • Medicare Percentage of members 18 years and older with multiple high-risk chronic conditions who had a follow-up service within 7 days of an ED visit during the measurement year.	Exclusions: N/A	Follow-up service: <u>Outpatient</u> POS: 03, 05, 07, 09, 11-20, 33, 49, 50, 71, 72 <u>Outpatient</u> CPT: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347, 99348-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99455, 99483; HCPCS: G0402, G0438, G0439, G0463, TI015 <u>Iransilional Care Management Services</u> CPT: 99487, 99486, 99470, 99491; HCPCS: G0506 <u>HOutpatient Visit</u> CPT: 99487, 99489, 99490, 99491; HCPCS: G0506 <u>HOutpatient Visit</u> CPT: 99487, 99489, 99470, 99491; HCPCS: G0505 <u>HOutpatient Visit</u> Partial Hospitalization POS: 52 Partial Hospitalization or Intensive Outpatient HCPCS: G0410, G0411, H0039, H0040, H2000, H2010, H2011, H2013 H2020, TI015 Partial Hospitalization POS: 53 <u>Electroconvulsive Therapy</u> CPT: 90870 <u>Telehealth Visit</u> POS: 02 <u>Ieleheoth Visit</u> CPT: 99266, 98667, 98968, 99441, 99442, 99443 POS: 02 <u>Ieleheoth Visit</u> CPT: 99260, 98967, 99078, 99201-99205, 99211-99215, 99241- 99245, 99341-9937, 993919, HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485 Community Mental Health Center POS: 53 <u>Electroconvulsive Therapy</u> CPT: 99860, 9867, 98968, 99441, 99442, 99443 POS: 02 Ieleheoth Visit CPT: 99860-98862, 99078, 99201-99205, 99211-99215, 99241- 99243, 99311- POS145, 99347-99350, 99384-99387, 99394-99387, 99394-99387, 99344-99350, 19444, 99445, 98485, 11004, 11012, UBREV: 0510, 0513, 0515-0517, 0519-0523, 0526- 0529, 0900, 0902-0907, 0911-0917, 0919, 0944, 0944, 0945, 0982, 0983 <u>Online Assessment</u> CPT: 9869-9872, 98980, 98981, 99421-99423, 99444, 99457, 99458 HCPCS



Overuse/Appropriateness		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Non-Recommended Cervical CancerScreening in AdolescentFemales (NCS)• Commercial & MedicaidPercentage of adolescent females 16-20 years of age who were screened unnecessarily for cervical cancer.*A lower rate indicates 	Exclusions: N/A	<u>Cervical Cytology</u> CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175; HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 <u>HPV Test</u> CPT: 87624, 87625; HCPCS: G0476
Non-Recommended PSA- Based Screening in Older Men (PSA)	Exclusions: N/A	<u>PSA Lab Test</u> CPT: 84152-84154; HCPCS: G0103
Medicare		
Percentage of men 70 years and older during the measurement year who were screened unnecessarily for prostate cancer using prostate- specific antigen (PSA) - based screening.		
*A lower rate indicates better performance.		



Overuse/Appropriateness		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Appropriate Treatment for Upper Respiratory Infection (URI)	Exclusions: N/A	<u>CWP Antibiotic Medications</u> Aminopenicillins (Amoxicillin, Ampicillin)
		Ampicillin) Beta-lactamase Inhibitors Amoxicillin-clavulanate, first generation cephalosporins (Cefadroxil, Cefazolin, Cephalexin), folate antagonist (Trimethoprim), lincomycin derivatives (Clindamycin), macrolides (Azithromycin, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate), natural penicillins (Penicillin G benzathine, Penicillin G potassium, Penicillin S potassium), penicillinase- resistant penicillins (Dicloxacillin), quinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin), second generation cephalosporins (Cefaclor, Cefprozil, Cefuroxime), sulfonamides (Sulfamethoxazole- trimethoprim), tetracyclines (Doxycycline, Minocycline, Tetracycline), third generation cephalosporins (Cefdinir, Cefixime, Cefpodoxime, Ceftibuten, Cefditoren, Ceftriaxone),
		Moxifloxacin, Ofloxacin), second generation cephalosporins (Cefaclor, Cefprozil, Cefuroxime), sulfonamides (Sulfamethoxazole- trimethoprim), tetracycline (Doxycycline, Minocycline Tetracycline), third generation cephalosporir (Cefdinir, Cefixime, Cefpodoxime, Ceftibuten



Overuse/Appropriateness		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Avoidance of Antibiotic Treatment for Acute Bronchitis (AAB) • Commercial, Medicaid & Medicare Percentage of members 3 months and older diagnosed with acute bronchitis who were not dispensed an antibiotic. *This measure has a 12- month window starting July 1 of the year prior to the measurement year and ending June 30 of the measurement year.	Exclusions: N/A	Antibiotic Prescriptions Aminoglycosides (Amikacin, Gentamicin, Streptomycin, Tobramycin), aminopenicillins (Amoxicillin, Ampicillin), beta- lactamase inhibitors (Amoxicillin- clavulanate, Ampicillin-sulbactam, Piperacillin-tazobactam), first generation cephalosporins (Cefadroxil, Cefazolin, Cephalexin), fourth generation cephalosporins (Cefepime), ketolides (Telithromycin), lincomycin derivatives (Clindamycin, Lincomycin), macrolides (Azithromycin, Clarithromycin, Erythromycin, Erythromycin ethylsuccinate, Erythromycin stearate), miscellaneous antibiotics (Aztreonam, Chloramphenicol, Dalfopristinquinupristin, Daptomycin, Linezolid, Metronidazole, Vancomycin), natural penicillins (Penicillin G benzathine-procaine, Penicillin G benzathine-procaine, Penicillin G potassium, Penicillin G procaine, Penicillin G sodium, Penicillin G potassium, Penicillin G benzathine), penicillin, Nafcillin, Oxacillin), quinolones (Ciprofloxacin, Moxifloxacin, Levofloxacin, Moxifloxacin, Cfloxacin), rifamycin derivatives (Rifampin), second generation cephalosporin (Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime), sulfonamides (Sulfadiazine, Sulfamethoxazole- trimethoprim), tetracyclines (Doxycycline, Minocycline, Tetracycline), third generation cephalosporins (Ceffainir, Cefditoren, Cefixime, Cefotaxime, Cefpodoxime, Ceftazidime, Cefpodoxime, Ceftazidime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftriaxone), urinary anti-infectives (Fosfomycin, Nitrofurantoin, Nitrofurantoin macrocrystals-monohydrate, Trimethoprim)



Overuse/Appropriateness		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Use of High Risk Medications in Older Adults (DAE) • Medicare The percentage of members 67 years of age and older who had at least two dispensing events for the same high-risk medication during the measurement year. *A lower rate indicates better performance.	Exclusions: N/A	High-Risk Medications Anticholinergics, first-generation antihistamines (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Diphenhydramine (oral), Dimenhydrinate, Doxylamine, Triprolidine) Anticholinergics, anti-Parkinson agents Benztropine (oral), Trihexyphenidyl), Antispasmodics (Atropine (exclude ophthalmic), Belladonna alkaloids, Chlordiazepoxide-clidinium, Dicyclomine, Hyoscyamine, Methscopolamine, Propantheline, Scopolamine], Antithrombotic [Dipyridamole, oral short-acting], Cardiovascular, alpha agonists, central [Guanfacine, Methyldopa], Cardiovascular, other [Disopyramide, Nifedipine, immediate release], Central nervous system, antidepressants [Amitriptyline, Amoxapine, Clomipramine, Desipramine, Imipramine], Central nervous system, barbitrates [Amobarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital], Central nervous system, vasodilators [Ergoloid mesylates, Isoxsuprine], Central nervous system, other [Meprobamate], Endocrine system, estrogens with or without progestins; include only oral and topical patch products [Conjugated estrogen, Strogens with Orwithout progestins; inclu



Overuse/Appropriateness		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Use of Opioids at High Dose (HDO) • Commercial, Medicaid & Medicare Proportion of members 18 years and older who received prescription opioids at a high dose for ≥15 days during the measurement year. *A lower rate indicates better performance.	Exclusions: N/A	The number of members whose average morphine milligram equivalent dose (MME) was ≥90 during the treatment period.
Use of Opioids from Multiple Providers (UOP) • Commercial, Medicaid & Medicare Proportion of members 18 years and older receiving prescription opioids for ≥15 days during measurement year who received opioids from multiple providers. *A lower rate indicates better performance.	Exclusions: N/A	 Three rates reported: Multiple prescribers (4 or more prescribers) Multiple pharmacies (4 or more pharmacies) Multiple prescribers & pharmacies (both 4 or more prescribers and 4 or more pharmacies)
 Risk of Continued Opioid Use (COU) Commercial, Medicaid & Medicare Percentage of members 18 years or older who have a new episode of opioid use during the measurement year that puts them at risk for continued opioid use. *A lower rate indicates better performance. 	Exclusions: N/A	 Two rates reported: 1. Percentage of members whose new episode of opioid use lasts at least 15 days in a 30-day period 2. Percentage of members whose new episode of opioid use last at least 31 days in 62-day period



Access/Availability of Care		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
 Adults Access to Preventive/ Ambulatory Health Services (AAP) Commercial, Medicaid & Medicare The percentage of members 20 years or older who had an ambulatory or preventive care visit during: Measurement year (Medicaid and Medicare) or Measurement year or the two years prior (Commercial) 	Exclusions: N/A	Ambulatory Visits CPT: 92002, 92004, 92012, 92014, 99201-99205, 99211- 99215, 99241-99245, 99304- 99310, 99315, 99316, 99318, 99324-99328, 99334-99337, 99341-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99461, 99483; HCPCS: G0402, G0438, G0439, G0463, T1015; ICD-10: Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81-Z02.83, Z02.89, Z02.9, Z76.1, Z76.2; Telephone Visit CPT: 98966, 98967, 98968, 99441, 99442, 99443 Online Assessment CPT: 98969-98972, 98980, 98981, 99421- 99423, 99444, 99457, 99458; HCPCS: G0071, G2010, G2012, G2061,G2062, G2063, G2250, G2251, G2252



Access/Availability of Care		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) • Commercial, Medicaid & Medicare Percentage of members 13 years of age and older with a new diagnosis of alcohol or other drug (AOD) abuse or dependence who received initial treatment within 14 days of the diagnosis and a follow-up visit within 34 days of the initiation.	Exclusions: N/A	Any of the following with a diagnosis matching the start date diagnosis cohort using one of the following: Alcohol abuse and dependence diagnoses, opioid abuse and dependence diagnoses, Inpatient Stay UBREV: 0100, 0101, 0110-0114, 0116-0124, 0126-0144, 0146-0154, 0156-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199-0204, 0206- 0214, 0219, 1000, 1001, 1002 IET Stand Alone Visits CPT: 989k0-98962, 99078, 99201-99205, 99211- 99215, 99241-99245, 99341-99345, 99347- 99350, 99384-99387, 99394-99397, 99401- 99404, 99408- 99409, 99411, 99412, 99483, 99510; HCPCS: G0155, G0176, G0177, G0396, G0397, G0409, G0410, G0411, G0443, G0463, H0001, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2010-H2020, H2035, H2036, S0201, 59480, 59484, 59485, 11006, 11012; UBREV: 0510, 0513, 0515-0517, 0519- 0523, 0526-0529, 0900, 0902-0907, 0911-0917, 0919, 0944, 0945, 0982, 0983 Observation CPT: 99217, 99218, 99219, 99220 IET Visits CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99225 Telephone Visit CPT: 98966, 98967, 98968, 99441, 99442, 99443 Online Assessment CPT: 989769-88772, 98980, 98981, 99421-99423, 99444, 99458: HCPCS: G0071, G2010, G2012, G2061, G2062, G2063, G2251-G2252 OUD Weekly Non-Drug Service HCPCS: G2071, G2074-G2077, G2080 OUD Monthly Office-Based Treatment HCPCS: G2086, G2087 Medication treatment dispensing event of alcohol use disorder treatment medications [Disulfiram (oral), naltrexone (oral and injectable], acamprosate (oral; and injectable], buccal film, sublingual tablet, injection, implant), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film.]]



Access/Availability of Care		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Exclusions: N/A	Psychosocial Care CPT: 90832-90834, 90836-90840, 90845-90847, 90849, 90853, 90875, 90876, 90880; HCPCS: G0176, G0177, G0409, G0411, H0004
• Commercial & Medicaid The percentage of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first- line treatment.		G0177, G0409-G0411, H0004, H0035-H0040, H2000, H2001, H2011- H2014, H2017-H2020, S0201, S9480, S9484, S9485



Use of Services			
HEDIS Measure Definition	Required Service/Documentation	Coding Tips	
Ambulatory Care (AMB)	Exclusions: N/A	N/A	
Medicaid			
Summary of utilization of ambulatory care in the following categories: outpatient visits including telehealth and ED visits.			
Inpatient Utilization – General Hospital/Acute Care (IPU)	Exclusions: N/A	N/A	
• Medicaid			
Summary of utilization of acute inpatient care in the following categories: maternity, surgery, medicine, total (sum of maternity, surgery, and medicine)			
Identification of Alcohol and Other Drug Services (IAD)	Exclusions: N/A	N/A	
Commercial, Medicaid & Medicare			
Summary of the number and percentage of members with an alcohol and other drug (AOD) claim who received the following chemical dependency services during the measurement year: Inpatient, intensive outpatient or hospitalization, outpatient or medication treatment, ED, telehealth, any service.			
Diagnosed Substance Use Disorders (DSU)	Exclusions: N/A	N/A	
Commercial, Medicaid & Medicare			
The percentage of members 13 years of age and older who were diagnosed with a substance use disorder during the measurement year			



Use of Services			
HEDIS Measure Definition	Required Service/Documentation	Coding Tips	
Plan All Cause Readmissions (PCR)	Exclusions: N/A	N/A	
Commercial, Medicaid & Medicare			
For members 18 years of age or older, number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.			
Hospitalization Following Discharge from a Skilled Nursing Facility (HFS)	Exclusions: N/A	N/A	
• Medicare			
For members 65 years of age and older, the percentage of skilled nursing facility discharges to the community that were followed by an unplanned acute hospitalization for any diagnosis within 30 and 60 days.			
Acute Hospital Utilization (AHU)	Exclusions: N/A	N/A	
Commercial & Medicare			
For members 18 and older, the acute impatient and observation stay discharges during the measurement year.			



Risk Adjusted Utilization		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Emergency Department Utilization (EDU)	Exclusions: N/A	N/A
Commercial & Medicare		
For members 18 and older, ED visits during the measurement year.		
Hospitalization for Potentially Preventable Complications (HPC)	Exclusions: N/A	N/A
Medicare		
For members 67 years of age and older, the rate of discharges for ambulatory care sensitive conditions (ACSC) per 1,000 members and the risk-adjusted ratio of observed to expected discharges for ACSC by chronic and acute conditions.		
Fall Risk Management (FRM) • Medicare	Exclusions: N/A	Discussing and managing fall risk
Assesses different facets of fall risk management.		



Measures Collected Through CAHPS Health Plan Survey			
HEDIS Measure Definition	Required Service/Documentation	Coding Tips	
Management Urinary Incontinence in Older Adults (MUI) Medicare Assesses the management of urinary incontinence in older adults. 	Exclusions: N/A	Discussing urinary incontinence and treatment	
 Physical Activity in Older Adults (PAO) Medicare Assesses different facets of promoting physical activity in older adults. 	Exclusions: N/A	Discussing and advising physical activity	
Flu Shots for Adults (FVA) Commercial & Medicaid Percentage of members 18-64 years who received a flu shot in the last year. 	Exclusions: N/A	Advising flu shot	
 Flu Shots in Older Adults (FVO) Medicare Percentage of members 65 years and older who received a flu shot in the last year. 	Exclusions: N/A	Advising flu shot	
 Medical Assistance with Smoking Cessation (MSC) Commercial, Medicaid & Medicare Assesses different facets of providing medical assistance with smoking and tobacco cessation. 	Exclusions: N/A	Advising smokers and tobacco users to quit, discussing cessation medications, and discussing cessation strategies	
 Pneumonia Vaccine Status (PNU) Medicare Percentage of members 65 years and older who received a pneumococcal vaccine during the measurement year. 	Exclusions: N/A	Advising pneumonia vaccine	



Electronic Clinical Data Systems (ECDS)		
HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Breast Cancer Screening (BCS-E) •Commercial, Medicaid, & Medicare	One or more mammograms any time on or between October 1, two years prior to the measurement year and December 31 of the measurement year.	<u>Mammography</u> CPT: 77061- 77063, 77065- 77067
Women 50-74 years of age who had a mammogram to screen for breast cancer.	Exclusions: <u>Bilateral Mastectomy</u> ICD-10: OHTVOZZ <u>Unilateral Mastectomy</u> CPT: 19180, 19200, 19220, 19240, 19303, 19304, 19305, 19306, 19307 Modifier: 50; History of Bilateral Mastectomy ICD-10 Z90.13	
Adult	Members 19 and older:	Adult Influenza Vaccine:
Immunization Status (AIS-E) • Commercial, Medicaid,	Influenza: Members who received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period.	CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90688, 90689, 90694, 90756
Medicare The percentage of members 19 years of age and older who are up to date on recommended	Td/Tdap: Members who received at least one Td vaccine or one Tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period.	<u>Td/Tdap:</u> Td CPT: 90714, 90718; Tdap CPT: 90715
routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster and pneumococcal.	Pneumococcal: Members who were administered at least one dose of an adult pneumococcal vaccine on or after the member's 19th birthday and before or during the measurement period.	<u>Zoster:</u> CPT: 90736, 90750 <u>Adult Pneumococcal Vaccine:</u> CPT: 90670, 90671, 90677, 90732
	Members 50 years and older:	
	Zoster: Members who received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine at least 28 days apart, any time on or after the member's 50th birthday and before or during the measurement period.	
	Exclusions: Members with anaphylaxis to any of the listed vaccines.	



Electronic Clinical Data Systems (ECDS)			
HEDIS Measure Definition	Required Service/Documentation	Coding Tips	
Prenatal Immunization Status (PRS-E)• Commercial and MedicaidThe percentage of deliveries in the measurement period in which members had received 	Influenza Vaccine: Deliveries where members received an adult influenza vaccine on or between July 1 of the year prior to the measurement period and the delivery date Idap: Deliveries where members received at least one Tdap vaccine during the pregnancy (including on the delivery date).	Adult Influenza Vaccine: CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90688, 90689, 90694, 90756 <u>Tdap:</u> CPT: 90715	
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) • Commercial, Medicaid, and Medicare The percentage of members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.	 <u>Follow-Up on Positive Screen.</u> The percentage of members who were screened for clinical depression using a standardized instrument. <u>Follow-Up on Positive Screen.</u> The percentage of members who received follow-up care within 30 days of a positive depression screen finding. 	Follow-up on Positive Screen codes Depression Case Management Encounter: CPT – 99366, 99492, 99493, 99494 HPCS - G0512, T1016, T1017, T2022, T2023 Follow-Up Visits: With Depression or Other Behavioral Health Condition CPT: 98960-98962, 98966-98972, 98980,98981,9907899201-99205, 99211-99215, 99241-99245, 99341- 99345,99347, 99348-99350, 99381- 99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483 HPCS: G0071, G0463, G2012, G2061-G2063, G2250-G2252, T1015 A dispensed antidepressant medication.	



HEDIS Measure Definition	Required Service/Documentation	Coding Tips
Social Need Screening and Intervention (SNS-E) • Commercial, Medicaid, and Medicare The percentage of members who were screened, using prespecified instruments, at least once during the measurement period for unmet food, housing and transportation needs, and received a corresponding intervention if they screened positive.	 Food Screening Members with a documented result for food insecurity screening performed. Food Intervention Members receiving a food insecurity intervention on or up to 30 days after the date of the first positive food insecurity screen (31 days total). Housing Screening Members with a documented result for housing instability, homelessness or housing inadequacy screening performed. Housing Intervention corresponding to the type of housing need identified on or up to 30 days after the date of the first positive housing screen (31 days total). Transportation Screening performed. Transportation Intervention corresponding to the type of housing need identified on or up to 30 days after the date of the first positive housing screen (31 days total). 	Food Insecurity: CPT: 96156, 96160, 96161, 97802, 97803, 97804 HPCS: S5170, S9470 Housing Instability: CPT: 96156, 96160, 96161 Transportation Insecurity: CPT: 96156, 96160, 96161

